Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Leukemia Research

Volumn 24, Issue 8, 2000, Pages 653-663

  Deeg, H Joachim ^a   Appelbaum, Frederick R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cytogenetic risk group; Hematopoietic stem cell transplantation; MDS; Organ toxicity; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULTHOOD; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CHILDHOOD; CYTOGENETICS; DONOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REVIEW; SURVIVAL; WHOLE BODY RADIATION;

EID: 0033915528     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00049-7     Document Type: Article

References (54)

1. Greenberg P.L. Myelodsyplastic syndrome. Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., McGlave P. Hematology: Basic Principles and Practice. 2000;1106 Churchill Livingstone, New York.
2. Sanz G.F., Sanz M.A., Vallespì T. et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395.
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C. The French-American-British (FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189.
4. Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079.
5. Greenberg P., Bishop M., Deeg J. et al. NCCN practice guidelines for the myelodysplastic syndromes. Oncology. 12:1998;53.
6. De Witte T. Stem cell transplantation in myelodysplastic syndromes (Review). Forum. 9:1999;75.
7. Horowitz M.M. Results of allogeneic stem cell transplantation for malignant disorders. Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., McGlave P. Hematology: Basic Principles and Practice. 2000;1573 Churchill Livingstone, New York.
8. Anderson J.E., Appelbaum F.R., Schoch G. et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 87:1996;51.
9. O'Donnell M.R., Long G.D., Parker P.M. et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J. Clin. Oncol. 13:1995;2973.
10. Ratanatharathorn V., Karanes C., Uberti J. et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 81:1993;2194.
11. Slattery J.T., Clift R.A., Buckner C.D. et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 89:1997;3055.
12. Nevill T.J., Shepherd J.D., Reece D.E., Barnett M.J., Nantel S.H., Klingemann H.G., Phillips G.L. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transpl. 10:1992;445.
13. Hsu C., Lin M.T., Tang J.L., Tien H.F., Wang C.H., Chen Y.C. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. J. Formosan Med. Assoc. 98:1999;157.
14. Deeg H.J., Shulman H.M., Anderson J.E. et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 95:2000;1188.
15. Petersdorf E.W., Gooley T.A., Anasetti C., Martin P.J., Smith A.G., Mickelson E.M., Woolfrey A.E., Hansen J.A. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 92:1998;3515.
16. Arnold R., De Witte T., van Biezen A., Hermans J., Jacobsen N., Runde V., Gratwohl A., Apperley J.F. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transpl. 21:1998;1213.
17. Bjerke J, Anasetti C, Gooley T, et al. Unrelated donor (URD) bone marrow transplantation (BMT) for refractory anemia (RA). Blood 1998;92 (Suppl 1):142a, 573 (Abstract).
18. Castro-Malaspina H, Collins JER, Gajewski J, Harris R, Ramsay N, Deeg HJ. Unrelated donor marrow transplantation for myelodysplastic syndromes (MDS). Blood 1997;90 (Suppl 1):106a, 465 (Abstract).
19. Anderson JE, Thomas ED. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS). Leuk Res 1997;21 (Suppl 1): S51(Abstract).
20. Boogaerts M.A. Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia (Review). Curr. Opin. Hematol. 5:1998;465.
21. Pagliuca A, Mijovic A, Jeanes A, Perry A, Mufti GJ. Delayed platelet regeneration following allogeneic peripheral blood progenitor cell transplantation for acute leukemia. Bone Marrow Transpl 1995; 15(Supp2): S29 (Abstract).
22. Runde V, De Witte T, Arnold R et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl 1998;21:255.
23. Appelbaum F.R., Barrall J., Storb R. et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann. Intern. Med. 112:1990;590.
24. Anderson J.E., Appelbaum F.R., Schoch G. et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol. 14:1996;220.
25. Anderson J.E., Appelbaum F.R., Deeg H.J., Storb R. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndrome. Leuk. Res. (Abstract). 23:1999;S83-S85.
26. Zang DY, Deeg HJ, Gooley T, Anderson JE, Anasetti C, Sanders J, Myerson D, Storb R, Appelbaum F. Treatment of chronic myelomonocytic leukemia by allogeneic marrow transplantation. Br J Haematol (in press).
27. Sobecks R.M., Le Beau M.M., Anastasi J., Williams S.F. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transpl. 23:1999;1161.
28. Friedberg J.W., Neuberg D., Stone R.M. et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 17:1999;3128.
29. Wilson CS, Traweek ST, Slovak ML, Niland JC, Forman SJ, Brynes RK. Myelodysplastic syndrome occurring after autologous bone marrow transplantation for lymphoma. Am. J. Clin. Pathol 1997;108:369.
30. Witherspoon R.P., Deeg H.J. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica. 84:1999;1085.
31. Leahey A.M., Friedman D.L., Bunin N.J. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transpl. 23:1999;21.
32. Ballen K.K., Gilliland D.G., Guinan E.C. et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transpl. 20:1997;737.
33. Hasle H., Arico M., Basso G. et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia. 13:1999;376.
34. Barnard D.R., Kalousek D.K., Wiersma S.R. et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: a report from the Childrens Cancer Group. Leukemia. 10:1996;5.
35. Locatelli F, Niemeyer C, Angelucci E Eurpoean Working Group on Myelodysplastic Syndrome in Childhood. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J. Clin. Oncol. 15:1997;566.
36. Creutzig U., Bender-Gotze C., Ritter J., Zimmermann M., Stollmann-Gibbels B., Korholz D., Niemeyer C. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia. 12:1998;652.
37. Davies S.M., Wagner J.E., DeFor T. et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br. J. Haematol. 96:1997;749.
38. Woolfrey A.E., Gooley T.A., Sievers E.L. et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood. 92:1998;3546.
39. Castagna L., El Weshi A., Bourhis J.H., Ribrag V., Naccache P., Vantelon J.M., Brault P., Pico J.L. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT) (Letter). Br. J. Haematol. 103:1998;284.
40. Bader P., Klingebiel T., Schaudt A. et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia. 13:1999;2079.
41. Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts: ongoing trials in humans (Editorial). Bone Marrow Transpl. 25:2000;345.
42. McSweeney P.A., Storb R. Mixed chimerism: preclinical studies and clinical applications (Review). Biol. Blood Marrow Transpl. 5:1999;192.
43. Storb R, McSweeney PA, Sandmaier BM. Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the 21st century. Transpl Proc (in press).
44. Beran M, Estey E, Kantarjian H. Emerging role of topoisomerase I inhibitors in the therapy of high risk MDS and CMML. Leuk Res 1999;23 (Suppl 1):S70, 183, Fifth International Symposium on Myelodysplastic Syndromes, Prague, Czech Republic, 21-24 April (Abstract).
45. Wattel E., Solary E., Leleu X. et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia. 13:1999;524.
46. De Witte T., van Biezen A., Hermans J. et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood. 90:1997;3853.
47. Appelbaum F.R., Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 12(suppl 1):1998;S25-S29.
48. Nevill T.J., Fung H.C., Shepherd J.D. et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 92:1998;1910.
49. Gersuk G.M., Beckham C., Loken M.R. et al. A role for tumor necrosis factor-, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 103:1998;176.
50. Shetty V., Mundle S., Alvi S. et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 20:1996;891.
51. Holler E., Kolb H.J., Mittermuller J. et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 86:1995;890.
52. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, Gooley T. Negative regulators of hemopoiesis and stroma function in patients with MDS. Leuk Lymphoma 2000;37:405.
53. Deeg HJ. Delayed complications after hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation, 2nd Edition. Boston: Blackwell Science, 1999. p. 776.
54. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 94:1999;1237.